🧾 What This Document Is

This is Dyne Therapeutics' Definitive Proxy Statement (DEF 14A). Think of it as the official agenda and background packet for the company's upcoming annual shareholder meeting. It’s sent so shareholders can vote on key company decisions.

👉 Why it matters: Your vote as a shareholder (if you own stock) helps steer the company. This document tells you what you're voting on and gives the details you need to decide.

🏢 What The Company Does

Dyne Therapeutics is a clinical-stage biotechnology company focused on developing treatments for muscle diseases.

👉 In simple terms: They work on drugs for serious genetic disorders affecting muscles, like myotonic dystrophy and Duchenne muscular dystrophy. They're not selling products yet; they're in the research and clinical trial phase.

📅 The Big Event: 2026 Annual Meeting

When: Friday, June 5, 2026, at 11:00 a.m. Eastern Time.
Where: 100% virtual. It's online only at www.proxydocs.com/DYN.
Who can vote: Shareholders who owned stock as of the "record date"—April 7, 2026.
Shares outstanding: 165,219,501 shares as of the record date.

🗳️ The 5 Key Proposals Shareholders Will Vote On

Here’s what’s on the ballot and the Board’s recommendation for each.

1. 👥 Elect Directors (Proposal 1)

What: Vote for three "Class III" directors to serve until 2029.
Nominees: David Lubner, Brian Posner, Jason Rhodes.
Board Says: Vote FOR all three.

2. 💰 Advisory Vote on Executive Pay (Proposal 2)

What: An "advisory vote" on the compensation of the top executives (the "Named Executive Officers").
Board Says: Vote FOR approval.
Why it matters: This is the annual "Say-on-Pay" vote. While non-binding, it signals shareholder sentiment on pay packages.

3. 📈 Increase Authorized Shares (Proposal 3)

What: Amend the company charter to double the number of authorized common shares from 200 million to 400 million.
Board Says: Vote FOR.
Why it matters: More shares gives the company flexibility for future needs—like raising capital, making acquisitions, or issuing employee stock—without needing another shareholder vote. It doesn't mean they will issue them now, just that they can.

4. ⚖️ Officer Exculpation (Proposal 4)

What: Add a provision to the charter that can shield company officers from personal liability for certain business decisions (where they act in good faith).
Board Says: Vote FOR.
Why it matters: This is a common corporate governance move to help attract and retain talented executives by reducing their personal legal risk for routine business actions.

5. ✅ Ratify Auditor (Proposal 5)

What: Ratify the appointment of Deloitte & Touche LLP as the company's independent accounting firm for 2026.
Board Says: Vote FOR.
Why it matters: This is a standard annual vote to keep the auditors in place. If shareholders reject it, the board will reconsider their appointment.

⚙️ Corporate Governance Snapshot

Board Structure: 9 directors, split into three classes with staggered terms. The Board separates the Chair (Jason Rhodes) and CEO (John G. Cox) roles.
Independence: The Board has determined that all directors are independent except for CEO John Cox.
Key Committees: Audit, Compensation, Nominating & Governance, and a Research & Development committee.

💵 Executive Compensation Highlights

The filing includes detailed tables showing what the top executives were paid. The big picture is that compensation is a mix of base salary, annual bonuses, and long-term equity awards (stock).

CEO John Cox's 2025 Total Compensation: $7.2 million. The majority ($5.7 million) was in the form of stock awards and option awards.
Philosophy: The company states its pay is designed to attract and retain talent in the competitive biotech industry and align executives' interests with long-term shareholder success.

🧠 The Analogy

Think of the annual shareholder meeting as a corporate "check-up and planning day." The proxy statement is the agenda sent to all the owners (shareholders). The items on the agenda are:

Re-appointing some of the lead doctors (directors).
Getting feedback on how the head doctors are being paid.
Asking for permission to print more ownership certificates (authorized shares) for future use.
Updating the rulebook to protect doctors from being sued for standard decisions.
Officially keeping the same outside accounting firm that checks the books.

🧩 Final Takeaway

This proxy statement outlines Dyne Therapeutics' plans to refresh its board, seek shareholder input on pay, secure financial flexibility, and uphold its governance standards. Your vote, as a shareholder, is your direct voice in approving these foundational aspects of the company's operation and future strategy.

DYN Proposes Doubling Authorized Shares at Annual Meeting